Rhythm Pharmaceuticals, Inc. RYTM Proceeds from Maturities, Prepayments and Calls of Short-Term Investments
Proceeds from Maturities, Prepayments and Calls of Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by Rhythm Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments.
The official record: Rhythm Pharmaceuticals, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Rhythm Pharmaceuticals, Inc.'s proceeds from maturities, prepayments and calls of short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Rhythm Pharmaceuticals, Inc.'s proceeds from maturities, prepayments and calls of short-term investments?
- Rhythm Pharmaceuticals, Inc. (RYTM) reported proceeds from maturities, prepayments and calls of short-term investments of $99.25M in Q1 2026.
- How has Rhythm Pharmaceuticals, Inc.'s proceeds from maturities, prepayments and calls of short-term investments changed year-over-year?
- Rhythm Pharmaceuticals, Inc.'s proceeds from maturities, prepayments and calls of short-term investments increased by 70.1% year-over-year, from $58.33M to $99.25M.
- What is the long-term trend for Rhythm Pharmaceuticals, Inc.'s proceeds from maturities, prepayments and calls of short-term investments?
- Over 4 years (2021 to 2025), Rhythm Pharmaceuticals, Inc.'s proceeds from maturities, prepayments and calls of short-term investments has grown at a -8.6% compound annual growth rate (CAGR), from $361.25M to $252.47M.